A number of ER-targeting drugs are approved for the treatment of the ER+ breast cancer subtype including the selective oestrogen receptor modulator (SERM) tamoxifen, the aromatase inhibitor (AI) letrozole, or the selective oestrogen receptor degrader (SERD) fulvestrant [3]. The gene discussed is ESR1; the disease is breast cancer.